These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 15054158

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM.
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [Abstract] [Full Text] [Related]

  • 23. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Sep 01; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 28. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec 01; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
    Vega E, Gonzalez D, Ghiringhelli G, Mautalen C.
    J Bone Miner Res; 1987 Aug 01; 2(4):267-71. PubMed ID: 3455613
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb 01; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 35. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C, Meinhardt U, Greenfield JR, De Winter J, Nguyen TV, Dunstan CR, Seibel MJ.
    Clin Lab; 2006 Feb 01; 52(1-2):1-10. PubMed ID: 16506358
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R, Krege JH, Chen P, Glass EV, Reginster JY.
    Curr Med Res Opin; 2006 Jan 01; 22(1):61-6. PubMed ID: 16393431
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martínez de Osaba MJ, Muñoz-Gómez J, Ballesta AM.
    Arthritis Rheum; 1997 Mar 01; 40(3):461-8. PubMed ID: 9082934
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.